Latest Breaking News & Top Headlines

29p depression pill found to reduce risk of hospitalization of unvaccinated patients


An inexpensive antidepressant could cut the risk of an unvaccinated Covid patient requiring hospital care by a third, a large Brazilian study suggests.

Fluvoxamine – available by prescription in the UK under the name Faverin – is believed to calm the immune system due to its anti-inflammatory properties.

It belongs to a class of drugs known as selective serotonin reuptake inhibitors, which are prescribed to about 70 million Britons each year.

The drug, which costs about 29 cents per tablet, was tested on nearly 741 people who tested positive within seven days and had underlying health conditions.

Patients received a daily course of two pills for 10 days. Of those who received the medication, 79 (10.6 percent) required hospital care, compared with 15.7 percent in the placebo group.

The researchers wrote in the paper that their analysis found that the pills reduced the risk of hospitalization by 32 percent.

They said the treatment could be used in third world countries with little access to vaccines because it is ineffective and could help patients.

But experts not involved in the trial said it needs to be tested in vaccinated patients to determine if it offers them any benefit and is safe.

Fluvoxamine – available by prescription as Faverin from 29p a tablet – found to reduce the risk of hospitalizations in Covid patients by a third

Fluvoxamine works by increasing the amount of serotonin in the brain, which can help improve a person’s mood.

Covid antibody therapy lowers hospitalization risk by 85 percent

Sotrovimab lowers risk of Covid hospitalization by 85 percent, study shows

Sotrovimab lowers risk of Covid hospitalization by 85 percent, study shows

Antibody therapy against Covid reduces a patient’s risk of being hospitalized by 85 percent, a study shows.

Sotrovimab – which is already being used in the US – was administered to nearly 600 patients in studies shortly after they tested positive for Covid and experienced symptoms.

Of the 291 who received the treatment, three were hospitalized.

But no one was admitted to intensive care or died of the disease.

In comparison, of the 292 who received the placebo, 21 were hospitalized.

Of these, five were later admitted to intensive care and one died of the disease.

Patients in the study – published in the New England Journal of Medicine – were 65 years old on average.

The drug uses a man-made antibody to fight Covid and is given through an injection.

Tests suggest that the antibodies work well against all variants, as well as against the original virus.

It costs $2,100 per dose and is made by Vir Biotechnology and GlaxoSmithKline.

The US Food and Drugs Agency (FDA) has already given it emergency approval.

And the European Commission has signed an agreement to purchase more than 220,000 doses.

But no orders for the treatment have been made in the UK.

The country’s regulators approved Ronapreve — an antibody cocktail used to treat Donald Trump — in August, but the doses were slow to arrive, leading to frustration among patients and doctors.

Based on interim results of studies, GlaxoSmithKline reported in May of this year that sotrovimab was 85 percent effective against hospitalization.

But the hormone is also involved in regulating the immune system and can help prevent it from overreacting and attacking healthy cells, which can be fatal.

Scientists in Brazil launched the study in January 2021, when Covid vaccines had just started rolling out.

The participants were recruited from 11 locations in Brazil. They were, on average, 50 years old and all had at least one underlying health condition, such as type 2 diabetes or high blood pressure.

About 741 people who had developed symptoms of the virus and tested positive up to seven days ago received the treatment.

Of those, 75 (10 percent) were hospitalized with the disease, but only one died after being infected with the virus.

Another 756 patients were placed in the placebo group and took a pill that did not contain the drug.

The results showed that 119 of them were hospitalized (15.7 percent) and another 12 (1.6 percent) died from the virus.

The researchers found no safety concerns with the drug, which is given to:

dr. Gilmar Reis, cardiologist at Belo Horizonte Hospital in Brazil and co-principal investigator of the study, said: “Our results are consistent with previous, smaller studies.

“Given the safety, tolerability, ease of use, low cost and widespread availability of fluvoxamine, these findings could have an important impact on national and international guidelines for clinical management of Covid.”

Professor Edward Mills, a health researcher at McMaster University in Canada, said the drug could be used for poorer countries.

He said: ‘Identifying low-cost, widely available and effective therapies against Covid is of great importance, and reusing existing drugs that are widely available and have well-understood safety profiles is of particular importance.’

Professor Penny Ward, a pharmaceutical doctor at King’s College London who was not involved in the study, said: ‘Fluvoxamine was identified as a potential treatment for covid based on its effects (as an antiviral agent) and impact on platelet function (reduction of the risk of inflammation).’

But she said: ‘Accordingly, while promising, especially because this product is inexpensive and could be made widely available, the impact on more severe outcomes remains uncertain.

In addition, given the level of protection against serious disease provided by vaccination, the potential additional benefit of this drug in alleviating breakthrough infections and disease is uncertain as vaccinated patients were excluded from the study.

In the future, the inclusion of patients with vaccine breakthrough infection in studies of community-based interventions will be important, and study protocols should be changed to allow for inclusion of this important subgroup with appropriate pre-treatment stratification and sample size adjustment to provide meaningful information. conclusions to be reached.’

The article was published in The Lancet Global Health.

It is part of the Brazilian government-funded TOGETHER study, which looks at promising existing treatments that can be reused to help Covid patients.


Leave A Reply

Your email address will not be published.